Drug intelligence / Profile preview

ELGN-EYE

Development stage: Unknown
Lead developer: Elgan Pharma
Modality: Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Ophthalmic

Overview

ELGN-EYE is a local drug developed by Elgan Pharma for the prevention of vision impairment caused by retinopathy of prematurity (ROP) in premature infants. This novel therapy is administered as specially formulated eye drops, utilizing insulin as a growth factor. Its mechanism involves stimulating normal retinal development, reducing inflammation, and mitigating oxidative stress to prevent damage to immature ocular blood vessels, which can lead to visual impairment or blindness. The drug is delivered via a tailored nanoemulsion formulation composed of infant-approved substances.

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on ELGN-EYE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELGN-EYE.

Explore the full profile